|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Department of Internal Medicine 1 and the
Department of Pathology, Kurume University School of Medicine,
Japan; R&D Laboratories, Research and Development Division,
Nippon Organon, Osaka, Japan; Department of Host Defense,
Research Institute for Microbial Diseases, Osaka University, Japan;
CREST of Japan Science and Technology Corporation, Suita, Japan;
Medical Research Council Laboratory of Molecular Biology,
Cambridge, United Kingdom; and Laboratory of Experimental
Immunology, National Cancer Institute-Frederick, MD.
Interleukin 18 (IL-18) was discovered as an interferon- Interstitial pneumonia represents a heterogeneous
group of idiopathic interstitial lung diseases that have a grave
prognosis. It can be clinically classified as an acute and a chronic
form (Bouros et al1; Michaelson et al2).
Acute interstitial pneumonia (AIP) is clinically characterized by a
rapid onset of respiratory failure and has a grave prognosis, with
greater than 70% mortality in 3 months, despite mechanical
ventilation. AIP is thought to be synonymous with Hamman-Rich syndrome,
occurring in patients without pre-existing lung diseases. It also
physiologically resembles acute respiratory distress syndrome (ARDS)
and occurs in a subset of patients with idiopathic ARDS. Chronic
interstitial pneumonia is also known as usual interstitial pneumonia
(UIP). It is characterized clinically by the insidious onset of a cough
and shortness of breath that slowly progresses to respiratory failure
and is characterized histopathologically by the random, nonuniform foci
of inflammation and fibrosis of the lung. UIP is often observed in aged
adults and in patients with a variety of conditions, including viral infections, rheumatoid diseases, and radiation treatment. Additionally, lethal UIP is often found in patients treated with chemotherapy. Bleomycin- and busulphan-induced3,4 lung fibrosis has been reported in patients undergoing treatment for malignancies, such as
squamous cell carcinoma and myeloid leukemia. Prevention of interstitial pneumonia/lung fibrosis is one of the most important issues in patients treated with chemotherapy.
Histologically, diffuse infiltration of mononuclear and
polymorphonuclear leukocytes into the lung is observed in the early stage of human interstitial pneumonia. Following the interstitial inflammation, florid fibroblast proliferation within both the interstitium and the alveolar space is found (proliferative stage). The
same pathology is observed in the lung fibrosis animal
model.1-8 Thus, the interstitial inflammation is thought
to be essential for the fibroblast proliferation of lung fibrosis. It
has become clear that multiple mediators may be involved in
establishing interstitial pneumonia/lung fibrosis, including cytokines,
chemokines, oxygen radicals, eicosanoids, prostaglandin, and
apoptosis-related genes.1-8 However, the
pathogenesis of interstitial pneumonia is not well understood.
Interleukin 18 (IL-18) was originally discovered as an interferon- We have reported that administration of IL-18 induced serum IgE
production and that IL-18 plus IL-2 treatment induced higher serum IgE
and IgG1 levels than seen with either IL-18 alone or IL-2 alone in
normal mice.17 Here we report that daily administration of
IL-18 with IL-2, but not IL-18 or IL-2 alone, induced a synergistic lethal effect caused by lung injury in normal but not in
IL-18R Mice
Reagents
In vivo treatment of mice with IL-18 and IL-2 Mice were treated once a day with an intraperitoneal injection of 200 µL rhIL-2 and/or rmIL-18, as indicated in "Results." These cytokines were suspended in sterile 200 µL phosphate-buffered saline (PBS), and mice treated with 200 µL PBS were used as controls. Following the treatment, mice were bled and killed, and wet lung, heart, and body weight were measured. The lungs were dried in an oven at 50°C for more than 48 hours, and dry lung weight was measured at 3 time points.In vivo administration of the metalloproteinase inhibitor Metalloproteinase inhibitor (KB-R7785) was suspended in sterile 0.5% carboxymethyl cellulose (CMC) at 10 mg/mL. Mice were treated once a day by an intraperitoneal injection of 0.2 mL KB-R7785, and 0.2 mL 0.5% CMC was used as a vehicle control. Administration of KB-R7785, used to prevent tumor necrosis factor (TNF-) and Fas ligand
(FasL) release in this study, was not toxic as previously reported.28
Pretreatment with antiasialo-GM1 Ab and anti-NK1.1 mAb Female SCID mice were pretreated by an intraperitoneal injection of 1 mg (100 µL) antiasialo-GM1 Ab (Wako, Tokyo, Japan) on days 0 and 7 to eliminate the NK cell population. SCID mice were then treated with control PBS or with IL-2 (100 000 IU) plus IL-18 (1 µg) once a day for 10 days. Normal rabbit serum (Dako Japan, Kyoto) was used as control.Antimouse CD4 (GK1.5, rat IgG2b), CD8 (2.43, rat IgG2b), and NK1.1 (PK136, mouse IgG2a) mAbs were used for in vivo depletion of T and NK cells as previously reported.17 Normal B6 mice were pretreated with 500 µg of each mAb at days 0 and 7. Mice were then daily treated with IL-2 (100 000 IU) plus IL-18 (1 µg) for 10 days. Purified rat IgG (Sigma Chemical, St Louis, MO) and mouse serum immunoglobulin were used as controls. Histological examinations For the histological analysis, mice were euthanized by an intraperitoneal injection of pentobarbital sodium (5 to 10 mg per mouse). After opening of the thorax, the lungs were immediately fixed by intratracheal instillation of 10% buffered formalin for 15 minutes, as previously reported.29 After the gross examination, the extracted tissues were placed in 10% formalin. Sections (4 µm thickness) were cut from paraffin-embedded tissues and placed on poly-l-lysine-coated slides and then incubated overnight at 55°C to 60°C. Deparaffinized sections were stained with hematoxylin and eosin (HE), and sequential sections were alternatively stained with the Elastica van Gieson (EVG) or Azan methods.Lymphocyte preparation and surface antigen analysis by flow cytometry B6 mice were treated with control PBS and with IL-2 (50 000 IU) plus IL-18 (1 µg) once a day as described above. At 6 hours after the fifth injection (4 days after treatment), mice were killed, and the lung tissues and pleural effusion were immediately harvested into PBS. Lung tissues were finely minced with surgical blades and then suspended with cold PBS. The cell suspension was passed through a cell strainer (Becton Dickinson, Franklin Lakes, NJ) and then washed with PBS. Spleen lymphocytes were also isolated as previously described.15 Then, 3-color analysis was performed by means of a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, CA). Antimouse CD16/CD32 mAb was used to block the nonspecific binding. More than 30 000 cells were analyzed in each fluorescence-activated cell sorter (FACS) analysis.Cytokine assays in the lung and serum Total RNA was isolated from the lungs by the RNeasy Midi Kit (Qiagen, Valencia, CA). Cytokine and chemokine messenger RNA (mRNA) expression was analyzed by RNase protection assay by means of the RiboQuant kit (PharMingen, Franklin Lakes, NJ) and 33P-uridine 5'-triphosphate-labeled riboprobe, set as previously described.15 For enzyme-linked immunosorbent assay (ELISA) measurement, the lung tissue was suspended and homogenized 1:4 (wt:vol) in sterile PBS containing 0.1% Tween 20 and centrifuged at 20 000g for 15 minutes; the supernatants were collected and stored at 80°C until assay, as previously
reported.30 The lung tissue supernatants and sera were
assayed by sandwich ELISA (R&D Systems, Minneapolis, MN).
Hydroxyproline assay Hydroxyproline assay was performed as described elsewhere.31Statistical analysis Results are expressed as the mean ± SD for the number per group. The difference between groups were analyzed by Wilcoxon signed rank test and, if appropriate, by paired t test. Survival curves were analyzed by the Kaplan-Meier log rank test. P < .05 was considered to be statistically significant.
IL-18 plus IL-2, but not IL-18 or IL-2 alone, induces death in normal mice Once-a-day administration of IL-18 (0.04 to 2 µg/d) or IL-2 alone (1000 to 1 million [Mil] IU/d) for 8 to 14 days did not induce lethality in normal B6 mice. Moreover, all B6 mice treated daily with 50 000 IU IL-2 or 0.2 µg IL-18 for 30 days survived (Figure 1A-B). However daily administration of IL-18 plus IL-2 was lethal in B6 mice in an IL-18 and IL-2 dose-dependent manner (IL-18 2 µg versus 0.5 µg, 0.1µg, or 0.04 µg, P < .05; IL-2 100 000 IU versus 10 000 IU or 1000 IU, P < .05) (Figure 1C-D). IL-18 plus IL-2, but neither cytokine alone, was able to induce death in normal B6, Balb/c, 129, and B6 × 129 mice. Although Balb/c, 129, and B6 × 129 mice were more resistant to the lethal effects of this cytokine combination than B6 mice (Figure 1E-F), overall the lethal effects induced by IL-18 plus IL-2 were not strain specific. Next, B6 × 129 IL-18R / and wildtype B6 × 129 mice were
treated daily with IL-18 (1 µg) plus IL-2 (50 000 IU) for 28 days.
None of the IL-18/IL-2-treated IL-18R/ mice died,
whereas all wildtype mice died within 18 days (Figure 1F). Moreover,
histological analysis revealed that no tissue damage was found in the
IL-18/IL-2-treated IL-18R/ mice (data not shown),
suggesting that the IL-18 plus IL-2 toxicity is IL-18
dependent.
IL-18 plus IL-2 induces interstitial NK cell infiltration in the lung but not other tissue damage Initially, we found that daily treatment with IL-18/IL-2 induced a lethal effect accompanied by pleural effusion in juvenile (younger than 10-week-old) female mice. Male or female mice older than 10 weeks also succumbed to IL-18/IL-2 treatment, but were more resistant than the juvenile female mice (data not shown). These results suggested that the body weight and sex could influence the lethality induced by IL-18/IL-2 treatment. In a general histological evaluation, moderate thymus atrophy and splenomegaly were found in IL-18/IL-2-treated mice, similar to that observed in IL-2-treated mice.16,32 Striking pathological changes in IL-18/IL-2-treated mice were limited to the lung while other organs, such as heart, liver, kidney, and intestine, showed only congestion. No brain damage was found in IL-18/IL-2-treated mice (data not shown). Daily administration of a high dose of IL-18 (1 µg IL-18 plus 50 000 IU IL-2) resulted in an acute lethal effect in juvenile B6 mice, usually within 4 days. Necropsy of these mice revealed that the alveolar wall and general interstitium had many nuclei with an interstitial infiltrate of mononuclear cells. Infiltrations of polymorphonuclear cells were also observed in the lesion, which was randomly distributed in the entire lung tissues. We did not observe that the lesions were dominated by hyaline membrane and proteinaceous debris, which is characteristic of the diffuse alveolar damage in humans (Figure 2A,C). The mice treated with a relatively low dose of IL-18 (0.1 to 0.2 µg) plus IL-2 (50 000 IU) demonstrated prolonged survival (longer than 1 week). In these mice, thickening of alveolar walls and interstitium was increased in a time-dependent manner and was accompanied by an infiltration of mononuclear cells, polymorphonuclear cells, and foam cells, which subsequently resulted in an architectural destruction and collapsed alveolar spaces (Figure 2B-C). In contrast, no significant histological change was found in the lungs of B6 mice treated daily with IL-18 (0.1 µg) alone or IL-2 (50 000 IU) alone for 30 days (Figure 2B). FACS analysis revealed that more than 40% of lymphocytes in the lung and pleural effusion of IL-18/IL-2-treated B6 mice were CD3NK1.1+ NK cells, while
CD3NK1.1+ NK cells were infrequently observed
in the lungs of control PBS-treated mice (Figure
3). Moreover, CD8+ T cells,
but not CD3NK1.1+ NK cells, were increased in
the spleen of IL-18/IL-2-treated B6 mice. In contrast,
CD3NK1.1+ NK cells, CD8+ T cells,
and CD3+NK1.1+ T cells were increased in the
spleen of B6 mice treated with IL-2 alone as previously
reported16,32 (data not shown). Thus, our
histopathological and FACS analyses suggest that NK cells accumulate
predominantly in the lung. This increase in NK cells may result in a
specific toxic effect on the lung but not other organs following the
IL-18 plus IL-2 treatment.
To verify whether IL-18/IL-2 can induce lung failure, we treated B6
mice daily with a control 200 µL PBS, 50 000 IU IL-2, 1 µg IL-18,
or 50 000 IU IL-2 plus 1 µg IL-18 for 8 days (n = 7 per group).
Then, mice were killed, and wet lung, dry lung, heart weight, and body
weight were measured. All of the IL-18/IL-2-treated B6 mice died
between 4 and 7 days after treatment, while all of the B6 mice treated
with PBS, IL-2 alone, or IL-18 alone survived. Both wet and dry lung
weights in IL-18/IL-2-treated B6 mice were significantly
(P < .05) higher than in control PBS-, IL-2-, and IL-18-treated B6 mice, although no significant difference in heart weight due to treatment was observed in these mice (data not shown). The lung wet-dry ratio in IL-18/IL-2-treated B6 mice was also significantly (P < .05) higher than that in control PBS-,
IL-2-, and IL-18-treated B6 mice (Figure
4A). The same results were observed in B6
mice treated daily with a low dose of IL-18 (0.1 µg) plus IL-2
(50 000 IU) for 30 days (data not shown).
Hydroxyproline content of lungs of IL-18/IL-2-treated mice We treated B6 mice daily with 200 µL PBS (control), 50 000 IU IL-2, 0.1 µg IL-18, or 50 000 IU IL-2 plus 0.1 µg IL-18 for 18 days (n = 5 each group). Then, mice were killed, and hydroxyproline content of lungs was measured. Our repeated experiments revealed a slight but significant increase of hydroxyproline content in the lungs of mice treated with IL-2 (50 000 IU) plus 0.1 µg IL-18 for 18 days (P < .05 versus PBS, IL-2, IL-18, and IL-18/IL-2 [treated on day 9]) (Figure 4B).Cytokine and chemokine expression in the serum and lungs of IL-18/IL-2-treated mice Next, we analyzed serum IFN- and TNF- protein levels in
IL-18/IL-2-treated mice, as previous studies have reported that TNF- and IFN- are involved in human interstitial pneumonia as well as the animal lung fibrosis model.1,2,7,8 Serum IFN- and TNF- protein levels in IL-18/IL-2-treated B6 mice
were significantly (P < .05) higher than those in B6 mice
treated with control PBS, IL-2 alone, or IL-18 alone (Figure
5A). We then analyzed lung cytokine and
chemokine levels in IL-18/IL-2-treated mice. B6 mice were treated with
control PBS, IL-2 (50 000 IU) alone, IL-18 (1 µg) alone, or IL-2
(50 000 IU) plus IL-18 (1 µg) once a day. At 2 hours after every
injection, mice were killed; the lung tissue was immediately harvested;
and total RNA was isolated. An RNase protection assay revealed that
various cytokine (IFN- IL-6, TNF-/ ) and chemokine
(lymphotactin [Ltn], RANTES, eotaxin, macrophage
inflammatory protein (MIP)-1, MIP-1, MIP-2, IP-10) mRNA
expression was induced in the lungs of IL-18/IL-2- but not IL-18- or
IL-2-treated B6 mice (data not shown). Moreover, the chemokine and
cytokine mRNA expression was up-regulated 1 day after treatment with
IL-18/IL-2, while little cytokine or chemokine mRNA or protein was
observed without stimulation (Figure 5B). We confirmed that IFN-,
IL-6, MIP-2, and MIP-1 protein levels in the lungs of
IL-18/IL-2-treated B6 mice were significantly (P < .05)
higher than those in control PBS-, IL-2-, and IL-18-treated B6 mice
(Figure 5C).
Metalloproteinase inhibitor cannot prevent IL-18/IL-2-induced lethality Our present study showed that TNF- production was induced in
the sera and lungs of IL-18/IL-2-treated mice. Thus, we wished to
determine whether a metalloproteinase inhibitor (KB-R7785) that
inhibits TNF- and FasL release28 can prevent this
lethal lung fibrosis model. All of the B6 mice treated with
KB-R7785/IL-18 plus IL-2 or with vehicle/IL-18 plus IL-2 succumbed
within 8 days, although KB-R7785 did not demonstrate any toxicity in
control PBS-treated B6 mice (Figure 6A).
Our results showed that KB-R7785 did not inhibit the lethal effects of
IL-18/IL-2 treatment.
IFN- / (GKO) and wildtype B6 mice
were treated daily with PBS, IL-2 (50 000 IU), IL-18 (1 µg), or
IL-18 (1 µg) plus IL-2 (50 000 IU) for 21 days. Three repeated
experiments revealed that 80% (16 of 20) of IL-18/IL-2-treated GKO
mice survived, while all of control B6 mice (n = 20)
died. Next, we treated GKO and B6 mice with a high dose of IL-18 (1 µg) plus a high dose of IL-2 (100 000 IU) for 21 days. These
experiments revealed that 40% (4 of 10) of GKO mice treated with IL-18
(1 µg) plus IL-2 (100 000 IU) survived, while all of the control
wildtype B6 mice (n = 10) died within 8 days (Figure 6B). Our
previous study showed that IL-18 in combination with IL-2 induced
TH2 cytokine (IL-4, IL-13), IgE, and IgG1 production in
vivo17 and in vitro.16 More recently,
Yoshimoto et al20 reported that IgE induction by IL-18 was
Stat6 dependent. Therefore, we wished to analyze whether the lethal
effect induced by IL-18/IL-2 is dependent on IL-4, IL-13, or Stat6. We
treated B6 IL-4/, B6 × 129 IL-13/,
B6 × 129 IL-4/IL-13/, B6 Stat6/, and
control wildtype mice once a day with IL-18 (1 µg) plus IL-2 (50 000
IU) for 10 days. All of these knockout and control wildtype B6 and
B6 × 129 mice died within 10 days after the treatment (Figure
6C).
NK-cell depletion prevents the lethal effect caused by IL-18/IL-2 administration We have analyzed juvenile SCID (T-cell- and B-cell-deficient) and Balb/c athymic nude (T-cell-deficient) mice to determine whether the IL-18 plus IL-2 toxicity is NK cell dependent. SCID, nude, and control Balb/c mice (n = 10) were treated daily with control PBS, IL-2 (50 000 IU) alone, IL-18 (1 µg) alone, or IL-18 (1 µg) plus IL-2 (50 000 IU). All of the IL-18/IL-2-treated SCID, nude, and Balb/c mice died within 14 days after treatment, while all mice treated with PBS, IL-2 alone, or IL-18 alone survived (data not shown). Next, we pretreated SCID mice with antiasialo-GM1 Ab at days 0 and 7 to deplete NK cells, and then treated the mice daily with IL-18 (1 µg) and IL-2 (100 000 IU). Surprisingly, lethality was completely eliminated by the pretreatment of SCID mice with antiasialo-GM1 Ab but not with control rabbit serum (Figure 7A). Next, we pretreated B6 mice with anti-NK1.1 mAb, anti-CD4 mAb, anti-CD8 mAb, rat IgG, or mouse immunoglobulin at days 0 and 7 and then treated the mice daily with IL-18 (1 µg) plus IL-2 (100 000 IU). IL-18/IL-2 lethality was completely eliminated by the pretreatment with anti-NK1.1 mAb. However, all of the IL-18/IL-2-treated B6 mice pretreated with anti-CD4 mAb, anti-CD8 Ab, or control antibody succumbed within 9 days (Figure 7B).
In this study, we have demonstrated that daily administration of a high dose of IL-18 (2 µg) alone or IL-2 (1 Mil IU) alone did not induce lethality in normal mice. However, in our experimental model, coadministration of IL-18 plus IL-2 induced a lethal effect in normal mice in an IL-18 or IL-2 dose-dependent manner. A high dose of IL-18 (more than 1 µg with 50 000 IU IL-2) resulted in acute death to juvenile B6 mice, usually within 4 days. In the mice treated with a high dose of IL-18 plus IL-2, severe lymphocyte infiltration, mainly by NK and polymorphonuclear cells, was found in the alveolar walls and general interstitium within 2 days, suggesting acute lung injury. In the mice treated with a relatively low dose of IL-18 (plus 50 000 IU IL-2) for 3 to 4 weeks, marked cellular infiltration and an architectural destruction associated with collapsed alveolar spaces were found in surviving B6 mice. In contrast, no tissue damage was observed in brain, heart, liver, kidney, and intestine in IL-18/IL-2-treated mice. Therefore, our present study revealed that coadministration of IL-18 plus IL-2 induced lethality by both acute and chronic lung injury in normal mice in an IL-18 dose-dependent manner. In the late 1980s, lymphokine-activated killer cells and IL-2 were administered to patients with metastatic cancer.33 The therapy produced significant side effects, mainly owing to the administration of large amounts of IL-2. Patients developed a capillary leak syndrome resulting in anasarca and multiple organ failure in an IL-2 dose-dependent manner. In some cases, the increase in vascular permeability led to varying degrees of interstitial pulmonary edema.33,34 Moreover, similar observations were reported in murine experimental models; the toxicity of large amounts of IL-2 administration was shown to be systemic, mediated by NK cells35 and TNF production.36 For example, Rosenstein and his colleagues37 reported that female 8- to 16-week-old B6 mice treated 3 times a day by an intraperitoneal injection of more than 200 000 IU IL-2 showed systemic vascular leak. Anderson et al38 also reported that administration of 600 000 IU IL-2 twice a day for 7 days induced lethality caused by vascular leak syndrome and hepatocyte necrosis in normal B6D2F1 mice. Here we report that administration of IL-2 alone (10 000 to 1 000 000 IU) once a day was not toxic, although IL-2 (more than 10 000 IU) induced lethal lung injury when combined with IL-18 (0.5 µg) in B6 mice (Figure 1). Thus, our present results and previous studies indicate that IL-2 alone cannot induce toxicity when B6 mice are treated with a relatively low dose of IL-2 once a day, although systemic (greater than twice a day) administration of a high dose of IL-2 alone is toxic. In our present study, a pharmacological blockade (matrix metalloproteinase inhibitor28) of TNF production did not prevent the toxicity of IL-18 plus IL-2, which is in contrast to the report of Fraker et al,36 where the toxicity induced by high-dose IL-2 was prevented by anti-TNF antibody. These results suggest that TNF-independent mechanisms are involved in the pathogenesis of lung injury induced by a relatively low dose of IL-2 plus IL-18, while toxicity (systemic vascular leak) by a high dose of IL-2 is TNF dependent. Bleomycin, a member of a glycopeptide group of antibiotics, is well known to induce lung fibrosis in humans as well as in rodents.3,5 Our present study showed that administration of IL-18 plus IL-2 induced acute lung injury, usually within 4 days, when a high dose of IL-18 (more than 1 µg) along with 50 000 IU IL-2 was administered to juvenile B6 mice. However, acute lung injury in these mice was not accompanied by hyaline membrane formation, which is considered to be the histological sign of human acute lung injury, such as AIP and ARDS.1,39 Similar observations were reported in the mouse model of bleomycin-induced lung fibrosis; formation of hyaline membrane was often found in the lungs of bleomycin-treated patients but not in a mouse bleomycin-fibrosis model.1,7,39 These results suggest that species difference accounts for the hyaline membrane formation in the process of acute lung injury. Administration of low-dose IL-18 (less than 0.2 µg) plus IL-2 (50 000 IU) resulted in a prolonged survival time. In these mice, interstitial infiltration of mononuclear cells and polymorphonuclear cells was observed followed by collapsed alveolar spaces. We also observed foam cells in the collapsed alveolar lesions. Moreover, the mean wet lung weight, lung wet-dry ratio, and, especially, dry lung weight in IL-18/IL-2-treated mice were significantly higher than in control PBS-, IL-2-, and IL-18-treated mice. Furthermore, the hydroxyproline content of the lung in IL-2 (50 000 IU)/IL-18 (0.1 µg)-treated mice (day 18), representing a quantitative analysis of collagen deposition,31 was significantly higher than in control mice (Figure 4). It has been reported that thickening of the alveolar walls with an accumulation of lymphocytes and foam cells was characteristic of the early stage of fibrous alveolitis, which subsequently augments the gradual increase of collagen synthesis.1,39 Thus, our histological and biochemical findings in the mice treated with low-dose IL-18 (less than 0.2 µg) plus IL-2 (50 000 IU) appear to represent an early stage of lung fibrosis. However, in these mice, we did not observe the distinct honeycombing structure that is usually observed in patients with end-stage pulmonary fibrosis1,39 (Figure 2). Thus, our lung injury model may be characteristic of persistent lymphocyte infiltration rather than distinct lung fibrosis. Lymphocytic interstitial pneumonia (LIP) is characterized by heavy lymphoid infiltrates but a lesser degree of fibrosis.1,2 The multiple nodular lymphocytic lesions resembling lymphoid hyperplasia or lymphoma that is prominent in patients with LIP were not observed in our present model. Thus, our mouse model of IL-18/IL-2-induced lung injury represents a novel animal model for elucidating lymphocytic infiltration (especially of NK cells) into the lung. We have found that IL-18/IL-2 lethal lung injury was not strain specific, but mortality differences were found between the highly susceptible B6 and the more resistant 129 strain. Similar strain differences are seen in the bleomycin-induced lung fibrosis model. For example, C57BL/6J and C3H/HeN mice are considered to be susceptible to bleomycin fibrosis, and Balb/c and C3H/fKam mice are relatively bleomycin resistant.40,41 However, our present study showed that all of the Balb/c mice succumbed to the IL-18/IL-2 treatment (Figure 1), suggesting that different mechanisms are involved in the pulmonary toxicity induced by bleomycin and IL-18/IL-2 treatment. In fact, it has been reported that administration of bleomycin induced distinct lung fibrosis associated with myofibloblastic proliferation,40,41 but less fibroblastic proliferation was found in our IL-18/IL-2-induced lung injury model. Here we propose that our mouse model of IL-18/IL-2-induced lethal lung injury represents a new animal model for human interstitial pneumonia. Previous studies have suggested that cytokines, such as IFN- Our present study shows that in vivo administration of IL-18/IL-2
induces death in both athymic nude (T-cell-deficient) and SCID (T- and
B-cell-deficient) mice. FACS and histological analysis found a diffuse
lymphocyte infiltration, composed mainly of
CD3 Many lines of evidence support the model that administration of IL-2,
IL-12, and IL-18 can be a particularly effective antitumor treatment.
Moreover, combination therapy with IL-12, IL-2, and IL-18 has
demonstrated synergistic antitumor activity.32,42-44 However, it has been reported that in vivo administration of IL-12 can
induce sepsis, shock, and death accompanied with intestinal damage in
synergy with IL-2 or IL-15.45 Recent studies have reported
that daily administration of IL-18 and IL-12 can synergistically induce
liver injury, diarrhea, hemorrhagic colitis, and fatty liver and can
result in a fatal inflammatory response in mice but not in
IFN- Interstitial lung diseases, including lung fibrosis, AIP, ARDS, and
UIP, have a grave prognosis. Current therapeutic strategies for
interstitial pneumonia/lung fibrosis are hardly effective, although
glucocorticoids are often used in therapy.1,2 Our results
raise the possibility that blocking of IL-18, IL-2, and/or IFN- In conclusion, we have shown that administration of IL-18 in combination with IL-2, but not IL-18 alone or IL-2 alone, induced lethal lung injury accompanied by marked interstitial lymphocyte infiltration in normal mice. This lethal effect was completely eliminated by the depletion of NK cells. These results suggest that IL-18, IL-2, and NK cells may play an important role in the pathogenesis of lung injury and interstitial pneumonia. Our study offers a potential model for the pathogenesis of interstitial pneumonia, which currently has an unknown etiology.
We thank Ms Chitose Harada, Ms Maki Tsuruta, Ms Emiko Kuma, and Ms Yumi Furushiro for technical assistance; Dr Kohichiro Yoshino (Japan Organon, Osaka) for providing metalloproteinase inhibitor (KB-R7785); and Dr Goro Matsuzaki (Kyusyu University, Fukuoka, Japan) for providing anti-NK1.1 mAb.
Submitted May 15, 2001; accepted October 15, 2001.
Supported by Kurume University School of Medicine Alumni Foundation (Japan), the Ishibashi Foundation for the Promotion of Science (Tokyo, Japan), Kaibara Morikazu Medical Science Promotion Foundation (Fukuoka, Japan), Mitsui Medical Science Promotion Foundation (Tokyo, Japan), The Promotion and Mutual Aid Corporation for Private Schools of Japan, and Grant-in-Aid for Scientific Research on Priority Areas (C) "Medical Genome Science" from the Ministry of Education, Science, Sports and Culture of Japan (T.H.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Tomoaki Hoshino, Department of Internal Medicine 1, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan; email: hoshino{at}med.kurume-u.ac.jp.
1. Bouros D, Nicholson AC, Polychronopoulos V, du Bois RM. Acute interstitial pneumonia. Eur Respir J. 2000;15:412-418[Abstract].
2.
Michaelson JE, Aguayo SM, Roman J.
Idiopathic pulmonary fibrosis: a practical approach for diagnosis and management.
Chest.
2000;118:788-794 3. Luna MA, Bedrossian CW, Lichtiger B, Salem PA. Interstitial pneumonitis associated with bleomycin therapy. Am J Clin Pathol. 1972;58:501-510[Medline] [Order article via Infotrieve].
4.
Heard BE, Cooke RA.
Busulphan lung.
Thorax.
1968;23:187-193 5. Chandler DB, Fulmer JD. The effect of deferoxamine on bleomycin-induced lung fibrosis in the hamster. Am Rev Respir Dis. 1985;131:596-598[Medline] [Order article via Infotrieve].
6.
Khalil N, Bereznay O, Sporn M, Greenberg AH.
Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation.
J Exp Med.
1989;170:727-737
7.
Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P.
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.
J Exp Med.
1989;170:655-663 8. Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature. 1990;344:245-247[CrossRef][Medline] [Order article via Infotrieve]. 9. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378:88-91[CrossRef][Medline] [Order article via Infotrieve]. 10. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol. 1998;10:259-264[CrossRef][Medline] [Order article via Infotrieve]. 11. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999;103:11-24[CrossRef][Medline] [Order article via Infotrieve]. 12. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000;12:59-63[CrossRef][Medline] [Order article via Infotrieve].
13.
Hyodo Y, Matsui K, Hayashi N, et al.
IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor.
J Immunol.
1999;162:1662-1668
14.
Xu D, Chan WL, Leung BP, et al.
Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells.
J Exp Med.
1998;188:1485-1492
15.
Hoshino T, Winkler-Pickett RT, Mason AT, Ortaldo JR, Young HA.
IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma.
J Immunol.
1999;162:51-59
16.
Hoshino T, Wiltrout RH, Young HA.
IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response.
J Immunol.
1999;162:5070-5077 17. Hoshino T, Yagita H, Ortaldo JR, Wiltrout RH, Young HA. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol. 2000;30:1998-2006[CrossRef][Medline] [Order article via Infotrieve].
18.
Hoshino T, Kawase Y, Okamoto M, et al.
Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function.
J Immunol.
2001;166:7014-7018
19.
Yoshimoto T, Tsutsui H, Tominaga K, et al.
IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils.
Proc Natl Acad Sci U S A.
1999;96:13962-13966 20. Yoshimoto T, Mizutani H, Tsutsui H, et al. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol. 2000;1:132-137[CrossRef][Medline] [Order article via Infotrieve].
21.
Wild JS, Sigounas A, Sur N, et al.
IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma.
J Immunol.
2000;164:2701-2710 22. Xu D, Trajkovic V, Hunter D, et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol. 2000;30:3147-3156[CrossRef][Medline] [Order article via Infotrieve].
23.
Leite-De-Moraes MC, Hameg A, Pacilio M, et al.
IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells.
J Immunol.
2001;166:945-951
24.
Hoshino K, Tsutsui H, Kawai T, et al.
Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor.
J Immunol.
1999;162:5041-5044 25. McKenzie GJ, Emson CL, Bell SE, et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity. 1998;9:423-432[CrossRef][Medline] [Order article via Infotrieve].
26.
McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie AN.
Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses.
J Exp Med.
1999;189:1565-1572 27. Takeda K, Tanaka T, Shi W, et al. Essential role of Stat6 in IL-4 signalling. Nature. 1996;380:627-630[CrossRef][Medline] [Order article via Infotrieve].
28.
Hattori K, Hirano T, Ushiyama C, et al.
A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice.
Blood.
1997;90:542-548 29. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J Clin Invest. 1995;96:250-259.
30.
Netea MG, Fantuzzi G, Kullberg BJ, et al.
Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia.
J Immunol.
2000;164:2644-2649 31. Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA. Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol. 1979;95:117-130[Abstract]. 32. Watanabe M, McCormick KL, Volker K, et al. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am J Pathol. 1997;150:1869-1880[Abstract]. 33. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485-1492[Abstract]. 34. Lotze MT, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986;58:2764-2772[CrossRef][Medline] [Order article via Infotrieve]. 35. Gately MK, Anderson TD, Hayes TJ. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. J Immunol. 1988;141:189-200[Abstract].
36.
Fraker DL, Langstein HN, Norton JA.
Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.
J Exp Med.
1989;170:1015-1020 37. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986;137:1735-1742[Abstract]. 38. Anderson TD, Hayes TJ, Gately MK, Bontempo JM, Stern LL, Truitt GA. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes: separation of efficacy and toxicity by selective lymphocyte subset depletion. Lab Invest. 1988;59:598-612[Medline] [Order article via Infotrieve]. 39. Kuhn C III, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140:1693-1703[Medline] [Order article via Infotrieve]. 40. Schrier DJ, Kunkel RG, Phan SH. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1983;127:63-66[Medline] [Order article via Infotrieve].
41.
Chen ES, Greenlee BM, Wills-Karp M, Moller DR.
Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin.
Am J Respir Cell Mol Biol.
2001;24:545-555 42. Fogler WE, Volker K, McCormick KL, Watanabe M, Ortaldo JR, Wiltrout RH. NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol. 1996;156:4707-4714[Abstract].
43.
Wigginton JM, Kuhns DB, Back TC, Brunda MJ, Wiltrout RH, Cox GW.
Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2.
Cancer Res.
1996;56:1131-1136
44.
Son YI, Dallal RM, Mailliard RB, Egawa S, Jonak ZL, Lotze MT.
Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells.
Cancer Res.
2001;61:884-888
45.
Carson WE, Yu H, Dierksheide J, et al.
A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.
J Immunol.
1999;162:4943-4951
46.
Carson WE, Dierksheide JE, Jabbour S, et al.
Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction.
Blood.
2000;96:1465-1473
47.
Nakamura S, Otani T, Ijiri Y, Motoda R, Kurimoto M, Orita K.
IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12.
J Immunol.
2000;164:3330-3336 48. National Institutes of Health. Guide for the Care and Use of Laboratory Animals. In: Clark JD, ed. Washington, DC: National Academy Press. Available at: http://oacu.od.nih.gov/regs/guide/guidex.htm. Accessed January 2001.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. Hoshino, M. Okamoto, Y. Sakazaki, S. Kato, H. A. Young, and H. Aizawa Role of Proinflammatory Cytokines IL-18 and IL-1{beta} in Bleomycin-Induced Lung Injury in Humans and Mice Am. J. Respir. Cell Mol. Biol., December 1, 2009; 41(6): 661 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Otulakowski, W. Duan, and H. O'Brodovich Global and Gene-Specific Translational Regulation in Rat Lung Development Am. J. Respir. Cell Mol. Biol., May 1, 2009; 40(5): 555 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Imaoka, T. Hoshino, S. Takei, T. Kinoshita, M. Okamoto, T. Kawayama, S. Kato, H. Iwasaki, K. Watanabe, and H. Aizawa Interleukin-18 production and pulmonary function in COPD Eur. Respir. J., February 1, 2008; 31(2): 287 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hoshino, S. Kato, N. Oka, H. Imaoka, T. Kinoshita, S. Takei, Y. Kitasato, T. Kawayama, T. Imaizumi, K. Yamada, et al. Pulmonary Inflammation and Emphysema: Role of the Cytokines IL-18 and IL-13 Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 49 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Woldbaek, J. B. Sande, T. A. Stromme, P. K. Lunde, S. Djurovic, T. Lyberg, G. Christensen, and T. Tonnessen Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H708 - H714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gangemi, V. Rapisarda, P. L. Minciullo, G. Di Pasquale, G. Lombardo, M. Valentino, and C. Fenga Circulating levels of interleukin-18 in asbestos-exposed workers Toxicology and Industrial Health, April 1, 2005; 21(3-4): 125 - 129. [Abstract] [PDF]
|
|
|
|
 |
|
 C. H. Yun, A. Lundgren, J. Azem, A. Sjoling, J. Holmgren, A.-M. Svennerholm, and B. S. Lundin Natural Killer Cells and Helicobacter pylori Infection: Bacterial Antigens and Interleukin-12 Act Synergistically To Induce Gamma Interferon Production Infect. Immun., March 1, 2005; 73(3): 1482 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Arras, J. Louahed, J.-F. Heilier, M. Delos, F. Brombacher, J.-C. Renauld, D. Lison, and F. Huaux IL-9 Protects against Bleomycin-Induced Lung Injury: Involvement of Prostaglandins Am. J. Pathol., January 1, 2005; 166(1): 107 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gendelman, N. Halligan, R. Komorowski, B. Logan, W. J. Murphy, B. R. Blazar, K. A. Pritchard Jr, and W. R. Drobyski Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration Blood, January 1, 2005; 105(1): 428 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kitasato, T. Hoshino, M. Okamoto, S. Kato, Y. Koda, N. Nagata, M. Kinoshita, H. Koga, D.-Y. Yoon, H. Asao, et al. Enhanced Expression of Interleukin-18 and its Receptor in Idiopathic Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol., December 1, 2004; 31(6): 619 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kinoshita, T. Yamagata, Y. Nozaki, M. Sugiyama, S. Ikoma, M. Funauchi, and A. Kanamaru Blockade of IL-18 Receptor Signaling Delays the Onset of Autoimmune Disease in MRL-Faslpr Mice J. Immunol., October 15, 2004; 173(8): 5312 - 5318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hoshino, H. Nakamura, M. Okamoto, S. Kato, S. Araya, K. Nomiyama, K. Oizumi, H. A. Young, H. Aizawa, and J. Yodoi Redox-active Protein Thioredoxin Prevents Proinflammatory Cytokine- or Bleomycin-induced Lung Injury Am. J. Respir. Crit. Care Med., November 1, 2003; 168(9): 1075 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Reddy, T. Teshima, G. Hildebrandt, D. L. Williams, C. Liu, K. R. Cooke, and J. L.M. Ferrara Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects Blood, April 1, 2003; 101(7): 2877 - 2885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Huaux, T. Liu, B. McGarry, M. Ullenbruch, and S. H. Phan Dual Roles of IL-4 in Lung Injury and Fibrosis J. Immunol., February 15, 2003; 170(4): 2083 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wigginton, J.-K. Lee, T. A. Wiltrout, W. G. Alvord, J. A. Hixon, J. Subleski, T. C. Back, and R. H. Wiltrout Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN-{gamma} and Fas-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-2 J. Immunol., October 15, 2002; 169(8): 4467 - 4474. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
mAb, PE-antimouse
NK1.1 mAb, and FITC-, PE-, Cy--conjugated isotype-matched
immunoglobulin were used for FACS analysis.
) and dry (
) lung weight
and lung wet-dry ratio in IL-18/IL-2-treated mice were significantly
(P < .05) higher than that in PBS, IL-2, and
IL-18-treated mice. (B) Hydroxyproline content of lungs of
IL-18/IL-2-treated mice. B6 mice (n = 5 per group) were daily given
control PBS, IL-2 (50 000 IU) alone, IL-18 alone (0.1 µg), or IL-18
(0.1 µg) plus IL-2 (50 000 IU) for 18 days. Then, mice were killed,
and hydroxyproline content of lungs was measured. *Significantly
(P < .05) higher than those in B6 mice treated with
control PBS, IL-2 alone, IL-18 alone, and IL-18/IL-2 (day-9
treatment).
B
and induces proinflammatory cytokines, such as TNF-